For non-small cell lung cancer, an anti-PD-L1 antibody drug has received regulatory approval based on the results of the PACIFIC study, a randomized, double-blind, placebo-controlled, multicenter phase III study of the anti-PD-L1 antibody drug administered sequentially in patients with unresectable locally advanced cancer (stage III) who did not show disease progression after curative concurrent chemoradiotherapy (CRT) using platinum drugs [75]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.